Literature DB >> 11796601

Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.

Karen A Near1, Anthony W Stowers, Dragana Jankovic, David C Kaslow.   

Abstract

Vaccination of mice with yeast-secreted Plasmodium yoelii-derived 19-kilodalton merozoite surface protein 1 (yMSP1(19)) has been shown to afford protection from challenge with a lethal strain of P. yoelii. Sterile immunity can be achieved when MSP1(19) is emulsified in Freund adjuvant but not when it is adsorbed to aluminum hydroxide gel (alum). Because complete Freund adjuvant is not an acceptable adjuvant for use in humans, alternative adjuvants must be identified for formulating MSP1(19) as a vaccine for use in humans. To determine whether oligodeoxynucleotides with CpG motifs (ODN), reported to be a powerful new class of adjuvants, could enhance the immunogenicity of yMSP1(19), C57BL/6 mice were vaccinated either with yMSP1(19) formulated with Freund adjuvant, with alum, or with ODN plus alum and challenged intravenously with P. yoelii 17XL asexual blood-stage parasites. Adsorption of immunogen and adjuvant to alum was optimized by adjusting buffer (phosphate versus acetate) and pH. We found that the adjuvant combination of ODN plus alum with yMSP1(19), injected intraperitoneally (i.p.), increased immunoglobulin G (IgG) yMSP1(19)-specific antibody production 12-fold over Freund adjuvant given i.p., 3-fold over Freund adjuvant given subcutaneously (s.c.), 300-fold over alum given i.p., and 48-fold over alum given s.c. The predominant antibody isotype in the group receiving alum-ODN-yMSP1(19) was IgG1. Increased antibody levels correlated to protection from a challenge with P. yoelii 17XL. Supernatant cytokine levels of gamma interferon in yMSP1(19)-stimulated splenocytes were dramatically elevated in the alum-ODN-yMSP1(19) group. Interleukin-10 (IL-10) levels were also elevated; however, no IL-5 was detected. The cytokine profile, as well as the predominant IgG1 antibody isotype, suggests the protective immune response was a mixed Th1/Th2 response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796601      PMCID: PMC127724          DOI: 10.1128/IAI.70.2.692-701.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.

Authors:  D Jankovic; P Caspar; M Zweig; M Garcia-Moll; S D Showalter; F R Vogel; A Sher
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

Authors:  M Roman; E Martin-Orozco; J S Goodman; M D Nguyen; Y Sato; A Ronaghy; R S Kornbluth; D D Richman; D A Carson; E Raz
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

3.  Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.

Authors:  C Hirunpetcharat; J H Tian; D C Kaslow; N van Rooijen; S Kumar; J A Berzofsky; L H Miller; M F Good
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

4.  CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants.

Authors:  G B Lipford; M Bauer; C Blank; R Reiter; H Wagner; K Heeg
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

5.  Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant.

Authors:  M F Chang; J L White; S L Nail; S L Hem
Journal:  PDA J Pharm Sci Technol       Date:  1997 Jan-Feb

6.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

Authors:  D M Klinman; A K Yi; S L Beaucage; J Conover; A M Krieg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

7.  Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.

Authors:  J H Tian; L H Miller; D C Kaslow; J Ahlers; M F Good; D W Alling; J A Berzofsky; S Kumar
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

8.  Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria.

Authors:  J B De Souza; K H Williamson; T Otani; J H Playfair
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

9.  Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

Authors:  W A Keitel; K E Kester; R L Atmar; A C White; N H Bond; C A Holland; U Krzych; D R Palmer; A Egan; C Diggs; W R Ballou; B F Hall; D Kaslow
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

10.  Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

Authors:  I T Ling; S A Ogun; P Momin; R L Richards; N Garçon; J Cohen; W R Ballou; A A Holder
Journal:  Vaccine       Date:  1997-10       Impact factor: 3.641

View more
  18 in total

1.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

2.  TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.

Authors:  Takahiro Tougan; Taiki Aoshi; Cevayir Coban; Yuko Katakai; Chieko Kai; Yasuhiro Yasutomi; Ken J Ishii; Toshihiro Horii
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

3.  Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.

Authors:  Pimmada Jeamwattanalert; Yuvadee Mahakunkijcharoen; Leera Kittigul; Pakpimol Mahannop; Sathit Pichyangkul; Chakrit Hirunpetcharat
Journal:  Clin Vaccine Immunol       Date:  2007-02-21

4.  Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.

Authors:  Garry L Morefield; Lynn D Hawkins; Sally T Ishizaka; Teri L Kissner; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

5.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Pepper mild mottle virus, a plant virus associated with specific immune responses, Fever, abdominal pains, and pruritus in humans.

Authors:  Philippe Colson; Hervé Richet; Christelle Desnues; Fanny Balique; Valérie Moal; Jean-Jacques Grob; Philippe Berbis; Hervé Lecoq; Jean-Robert Harlé; Yvon Berland; Didier Raoult
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

7.  Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Authors:  Shigeto Yoshida; Hiroshi Nagumo; Takashi Yokomine; Hitomi Araki; Ayaka Suzuki; Hiroyuki Matsuoka
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice.

Authors:  Zhong Su; Mi-Fong Tam; Dragana Jankovic; Mary M Stevenson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Authors:  Feng Qian; Kelly M Rausch; Olga Muratova; Hong Zhou; Guanhong Song; Ababacar Diouf; Lynn Lambert; David L Narum; Yimin Wu; Allan Saul; Louis H Miller; Carole A Long; Gregory E D Mullen
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

10.  CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Authors:  Sanjai Kumar; Trevor R Jones; Miranda S Oakley; Hong Zheng; Shanmuga P Kuppusamy; Alem Taye; Arthur M Krieg; Anthony W Stowers; David C Kaslow; Stephen L Hoffman
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.